PubMed

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM.

Diabetes. 2008 Jun;57(6):1723-9. Epub 2008 Mar 20.PMID: 18356408 [PubMed - indexed for MEDLINE]Related articlesFree article

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. Epub 2006 Oct 18.PMID: 17050778 [PubMed - indexed for MEDLINE]Related articlesFree article

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

List JF, Woo V, Morales E, Tang W, Fiedorek FT.

Diabetes Care. 2009 Apr;32(4):650-7. Epub 2008 Dec 29.PMID: 19114612 [PubMed - indexed for MEDLINE]Related articlesFree article

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.

Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M.

Eur J Pharmacol. 2009 May 1;609(1-3):148-54. Epub 2009 Mar 10.PMID: 19281809 [PubMed - indexed for MEDLINE]Related articles

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN.

J Med Chem. 2008 Mar 13;51(5):1145-9. Epub 2008 Feb 9.PMID: 18260618 [PubMed - indexed for MEDLINE]Related articles

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):513-9. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558. PMID: 19129749 [PubMed - indexed for MEDLINE]Related articles

Dapagliflozin: an emerging treatment option in type 2 diabetes.

Kipnes M.

Expert Opin Investig Drugs. 2009 Mar;18(3):327-34. Review.PMID: 19243283 [PubMed - indexed for MEDLINE]Related articles

Dapagliflozin for the treatment of type 2 diabetes.

Brooks AM, Thacker SM.

Ann Pharmacother. 2009 Jul;43(7):1286-93. Epub 2009 Jul 7. Review.PMID: 19584379 [PubMed - indexed for MEDLINE]Related articles

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. Epub 2008 Jun 26.PMID: 18583547 [PubMed - indexed for MEDLINE]Related articlesFree article

Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.

Zhang X, Urbanski M, Patel M, Cox GG, Zeck RE, Bian H, Conway BR, Beavers MP, Rybczynski PJ, Demarest KT.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1696-701. Epub 2005 Dec 27.PMID: 16380256 [PubMed - indexed for MEDLINE]Related articles

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):520-6. Epub 2009 Jan 7.PMID: 19129748 [PubMed - indexed for MEDLINE]Related articles

Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats.

Tabatabai NM, Sharma M, Blumenthal SS, Petering DH.

Diabetes Res Clin Pract. 2009 Jan;83(1):e27-30. Epub 2008 Dec 17.PMID: 19095325 [PubMed - indexed for MEDLINE]Related articles

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Bakris GL, Fonseca VA, Sharma K, Wright EM.

Kidney Int. 2009 Jun;75(12):1272-7. Epub 2009 Apr 8. Review.PMID: 19357717 [PubMed - indexed for MEDLINE]Related articles

T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.

Adachi T, Yasuda K, Okamoto Y, Shihara N, Oku A, Ueta K, Kitamura K, Saito A, Iwakura I, Yamada Y, Yano H, Seino Y, Tsuda K.

Metabolism. 2000 Aug;49(8):990-5.PMID: 10954015 [PubMed - indexed for MEDLINE]Related articles

Sodium-glucose cotransporter inhibitors for diabetes.

Isaji M.

Curr Opin Investig Drugs. 2007 Apr;8(4):285-92. Review.PMID: 17458177 [PubMed - indexed for MEDLINE]Related articles

Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats.

Nawano M, Oku A, Ueta K, Umebayashi I, Ishirahara T, Arakawa K, Saito A, Anai M, Kikuchi M, Asano T.

Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E535-43.PMID: 10710509 [PubMed - indexed for MEDLINE]Related articlesFree article

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Jabbour SA, Goldstein BJ.

Int J Clin Pract. 2008 Aug;62(8):1279-84. Review.PMID: 18705823 [PubMed - indexed for MEDLINE]Related articles

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.

Ellsworth BA, Meng W, Patel M, Girotra RN, Wu G, Sher PM, Hagan DL, Obermeier MT, Humphreys WG, Robertson JG, Wang A, Han S, Waldron TL, Morgan NN, Whaley JM, Washburn WN.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4770-3. Epub 2008 Jul 31.PMID: 18707880 [PubMed - indexed for MEDLINE]Related articles

A 96-well automated method to study inhibitors of human sodium-dependent D-glucose transport.

Castaneda F, Kinne RK.

Mol Cell Biochem. 2005 Dec;280(1-2):91-8.PMID: 16311909 [PubMed - indexed for MEDLINE]Related articles

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

Abdul-Ghani MA, DeFronzo RA.

Endocr Pract. 2008 Sep;14(6):782-90. Review.PMID: 18996802 [PubMed - indexed for MEDLINE]Related articles